Get Ready for Hep C Meds Mavyret and Vosevi
You'll see big changes in treating hepatitis C due to the new oral antivirals, Mavyret and Vosevi.
Expect to get more involved in managing hep C...just like you're managing heart disease, diabetes, etc. The newer hep C meds are easier to initiate, require less monitoring, and are better tolerated.
Mavyret (MAV-ih-reht, glecaprevir/pibrentasvir) will be another game changer. It's the first hep C med approved for just 8 weeks for initial therapy of all genotypes for most patients without cirrhosis.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote